{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(Suppl 1)"],"submitter":["Fitz-Patrick D"],"pubmed_abstract":["Abstract <h4>Background</h4> Because of the number and variability of serotypes causing pneumococcal disease among different geographic regions, age groups, and environmental backgrounds, expanding serotype coverage with pneumococcal conjugate vaccines (PCVs) is a continued unmet need. <h4>Methods</h4> This phase 1, randomized, double-blind study included healthy Japanese adults aged 18–49 years residing in the United States. Subjects were randomized 1:1:1 to receive a single dose of a 20-valent PCV (containing 13-valent PCV [PCV13] serotypes plus 8, 10A, 11A, 12F, 15B, 22F, 33F), a novel pneumococcal polysaccharide conjugate vaccine with extended coverage, or PCV13 (control). Safety was the primary endpoint and included reactogenicity events occurring ≤ 14 days after vaccination, adverse "],"journal":["Open forum infectious diseases"],"pagination":["S30-S31"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7776113"],"repository":["biostudies-literature"],"pubmed_title":["16. A Randomized Phase 1 Study of a Novel Pneumococcal Conjugate Vaccine in Healthy Japanese Adults in the United States"],"pmcid":["PMC7776113"],"pubmed_authors":["Peng Y","Watson W","Scott D","Baugher G","Gruber W","Scully I","Fitz-Patrick D","Jansen K","Young Jr. M"],"additional_accession":[]},"is_claimable":false,"name":"16. A Randomized Phase 1 Study of a Novel Pneumococcal Conjugate Vaccine in Healthy Japanese Adults in the United States","description":"Abstract <h4>Background</h4> Because of the number and variability of serotypes causing pneumococcal disease among different geographic regions, age groups, and environmental backgrounds, expanding serotype coverage with pneumococcal conjugate vaccines (PCVs) is a continued unmet need. <h4>Methods</h4> This phase 1, randomized, double-blind study included healthy Japanese adults aged 18–49 years residing in the United States. Subjects were randomized 1:1:1 to receive a single dose of a 20-valent PCV (containing 13-valent PCV [PCV13] serotypes plus 8, 10A, 11A, 12F, 15B, 22F, 33F), a novel pneumococcal polysaccharide conjugate vaccine with extended coverage, or PCV13 (control). Safety was the primary endpoint and included reactogenicity events occurring ≤ 14 days after vaccination, adverse ","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Oct","modification":"2025-04-19T01:19:24.077Z","creation":"2021-02-20T21:00:48Z"},"accession":"S-EPMC7776113","cross_references":{}}